Since each tissue type exhibits unique traits such as vascularization, immune profile, and biomechanical properties, tailored approaches are essential for optimal treatment
As we have documented the tolerability of L-PAM+BSO when supported by autologous stem cell infusion in heavily pretreated relapsed and/or refractory neuroblastoma patients (NANT phase I study, NCT00005835, www.clinicaltrials.gov), using myeloablative L-PAM+BSO is clinically feasible
Transwell assay and wound healing assay showed that BPC-157 significantly promoted migration of HUVECs
Clinical data show a 30% reduction in INR coefficient of variation and a 40% decrease in bleeding risk in the combination group, while maintaining stable anticoagulation efficacy
of B12 plus Iron, Liver, B Complex, and other vitamins and enzymes essential to good health and well being